L&C BIO Co.,LTD (KOSDAQ: A290650)
Health Care · Biotechnology · KR
₩51,000.00
-6.76% today · +65.0% 1Y
L&C BIO Co.,LTD (KOSDAQ: A290650) operates in the Biotechnology industry within the Health Care sector. The company is valued at $992.47M.
Over the last twelve months the share price has gained 65.0%, trading between 29.15K and 125.00K.
Tweenvest scores L&C BIO Co.,LTD across four factors: quality 49/100, value 54/100, dividend 3/100. Its strongest factor is value.
A290650 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $992.47M
- Revenue (TTM)
- $64.45M
- P/E
- —
- EPS
- -5,565.41
- Dividend yield
- 0.10%
- Beta (5Y)
- 1.49
- 52-week high
- ₩125,000.00
- 52-week low
- ₩29,150.00
- Avg volume (3M)
- —
- Shares outstanding
- 26.97M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.75 | -0.02% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.31 | -0.33% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.